View Financial HealthCyclerion Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Cyclerion Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-25.1%자사주 매입 수익률총 주주 수익률-25.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew major risk - Financial position Apr 02Korsana Biosciences, Inc. entered into a definitive merger agreement to acquire Cyclerion Therapeutics, Inc. (NasdaqCM:CYCN) for approximately $270 million in a reverse merger transaction.Apr 02High number of new and inexperienced directors Mar 01Cyclerion Therapeutics, Inc. Receives Positive Written Regulatory Feedback and Responses from the FDA on CYC-126's Phase 2 POC study in TRD and Its Path to Potential Regulatory ApprovalFeb 18+ 1 more updateNew major risk - Revenue and earnings growth Feb 03Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant DepressionJan 06New major risk - Shareholder dilution Nov 17New major risk - Financial position Aug 06New minor risk - Shareholder dilution May 13Cyclerion Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.May 08New major risk - Financial position May 08Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 16, 2025Apr 30Cyclerion Therapeutics, Inc. announced that it has received $1.374995 million in funding from J. Wood Capital Advisors LLC, Polaris Founders Capital and other investorsMar 26Cyclerion Therapeutics, Inc. Announces Promotion of Regina Graul to Chief Executive OfficerAug 07+ 1 more updateCyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024Apr 20Cyclerion Therapeutics, Inc. Appoints Regina Graul as PresidentDec 04Cyclerion Therapeutics, Inc. Announces Board of Directors AppointmentsDec 01Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as DirectorNov 25Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial OfficerOct 25New major risk - Financial position Jul 30First half 2023 earnings released: US$5.00 loss per share (vs US$12.14 loss in 1H 2022) Jul 30New major risk - Market cap size Jul 02Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in fundingMay 26High number of new and inexperienced directors May 24J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.May 13First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.30 loss in 1Q 2022) May 13Full year 2022 earnings released: US$1.01 loss per share (vs US$1.32 loss in FY 2021) Mar 24Cyclerion Therapeutics Announces an Extended Listing Compliance PeriodNov 30Price target decreased to US$4.00 Nov 16Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) Nov 05Cyclerion stock tanks 32% on workforce reduction, clinical development refocus Oct 06Consensus revenue estimates fall by 54% Aug 19Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 11We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn RateAug 09Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with SchizophreniaJul 29Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of DirectorsJul 27Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease FoundationJun 29Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial DiseaseJun 18Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 SymposiumJun 11Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price RequirementJun 04High number of new directors May 31Consensus forecasts updated May 11First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 06Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline ProgressMay 05Price target increased to US$10.50 Apr 27High number of new directors Apr 27Consensus revenue estimates fall by 49% Mar 06We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn RateMar 03Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 27Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline UpdatesFeb 25Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular PathologyJan 27Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.59 loss in 3Q 2020) Nov 12Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders Oct 26Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC StimulatorSep 24Independent Director Kevin Churchwell has left the company Aug 20Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.70 loss in 2Q 2020) Jul 31Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021Jul 23Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value IndexJun 28+ 5 more updatesCyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021 Jun 21Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris PartnersJun 05Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in PharmacologyMay 28CEO & Director recently bought US$1.7m worth of stock May 09First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2020) May 03Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like EpisodesApr 29Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical OfficerMar 20Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?Mar 09Full year 2020 earnings released: US$2.56 loss per share (vs US$4.49 loss in FY 2019) Feb 28Earnings beat expectations Feb 28New 90-day high: US$3.61 Feb 03What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?Jan 28Cyclerion Therapeutics Announces Clinical and Scientific Advisory BoardsJan 26New 90-day high: US$3.60 Jan 14President & Chief Scientific Officer notifies of intention to sell stock Jan 02President & Chief Scientific Officer recently sold US$61k worth of stock Jan 01Cyclerion Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective January 1, 2021Dec 23Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?Dec 20Chief Innovation Officer recently bought US$316k worth of stock Nov 15Third quarter 2020 earnings released: US$0.59 loss per share Nov 07Revenue and earnings beat expectations Nov 07Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly SubjectsOct 15+ 1 more updateNew 90-day low: US$3.35 Oct 15Cyclerion Therapeutics, Inc. Provides an Update on the Timing of Disclosing Top Line Results of Two Clinical TrialsOct 04Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000 Growth IndexJul 03지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CYCN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CYCN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Cyclerion Therapeutics 배당 수익률 vs 시장CYCN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CYCN)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.6%분석가 예측 (CYCN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CYCN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CYCN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CYCN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CYCN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 15:40종가2026/05/04 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cyclerion Therapeutics, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Pete StavropoulosCantor Fitzgerald & Co.Joon So LeeTruist SecuritiesDavid BautzZacks Small-Cap Research
Korsana Biosciences, Inc. entered into a definitive merger agreement to acquire Cyclerion Therapeutics, Inc. (NasdaqCM:CYCN) for approximately $270 million in a reverse merger transaction.Apr 02
Cyclerion Therapeutics, Inc. Receives Positive Written Regulatory Feedback and Responses from the FDA on CYC-126's Phase 2 POC study in TRD and Its Path to Potential Regulatory ApprovalFeb 18+ 1 more update
Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant DepressionJan 06
Cyclerion Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.May 08
Cyclerion Therapeutics, Inc. announced that it has received $1.374995 million in funding from J. Wood Capital Advisors LLC, Polaris Founders Capital and other investorsMar 26
Cyclerion Therapeutics, Inc. Announces Promotion of Regina Graul to Chief Executive OfficerAug 07+ 1 more update
J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.May 13
Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with SchizophreniaJul 29
Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of DirectorsJul 27
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease FoundationJun 29
Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial DiseaseJun 18
Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 SymposiumJun 11
Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price RequirementJun 04
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular PathologyJan 27
Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC StimulatorSep 24
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021Jul 23
Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value IndexJun 28+ 5 more updates
Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris PartnersJun 05
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in PharmacologyMay 28
Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like EpisodesApr 29
Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical OfficerMar 20
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?Jan 28
Cyclerion Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective January 1, 2021Dec 23
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?Dec 20
Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly SubjectsOct 15+ 1 more update
Cyclerion Therapeutics, Inc. Provides an Update on the Timing of Disclosing Top Line Results of Two Clinical TrialsOct 04
